Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype
Instead of relying primarily on historical relationships, many sponsors are exploring more data-driven approaches to site selection, including: regional disease heatmaps investigator performance analytics patient population modeling AI-assisted feasibility analysis These approaches aim to answer a fundamental question: Which sites can actually recruit the patients required for modern metabolic trials
The shoulder starts feeling more stable and predictable
Multiple GLP-1R agonists have entered into clinical trials, with some, such as semaglutide, progressing to approval
Zhang L, Ludden CM, Cullen AJ, Tew KD, Branco de Barros AL, Townsend DM